托马克联合治疗肺癌Ⅲ期临床观察  

Clinical Effect of Chemotherapy Combining TMK (Vindesine VDS) in the Treatment of Advanced Lung Cancer

作　　者：张树才[1] 杨新杰[1] 胡范彬[1] 范晓方 王群会[1] 顾艳斐[1] 吴卫华 

机构地区：[1]北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中国肿瘤》1998年第8期26-27,共2页China Cancer

摘　　要：［目的］观察托马克（长春地辛VDS）对原发性肺癌的疗效。[方法]应用含托马克的联合化疗对59例晚期原发性支气管肺癌患者进行了Ⅲ期临床研究。其中非小细胞肺癌（NSCLC）50例，小细胞肺癌（SCLC）9例。（结果）肺癌化疗总有效率达54．2％，NSCLC及SCLC有效率分别为50．0％及77．8％。化疗毒副反应以骨髓抑制、胃肠道反应及脱发为主。［结论］托马克的临床疗效及毒副反应与国外长春地辛同类产品相似。可广泛应用于支气管肺癌的临床治疗中。[Purpose] To analyze the therapeutic effectiveness of TMK(Vindesine VDS)for lung cancer. [Methods]Fiftynine patients with advaced primary lung cancer were entered into a stage Ⅲ clinical study of chemotherapy combining Vindesine (VDS). There were 50 patients with non-small cell lung cancer(NSCLC), 9 patients with small cell lung cancer(SCLC).[Results] An overall response rate of 54.2% was yielded in the patients with lung cancer. The response rates in NSCL and SCLC were 50.0% and 77.8%, respectively. The side-effects of chemotherapy were marrow inhibition, gastrointestinal response and lose one s hair.[Conclusion] The therapeutic effectiveness and side-effects of Vindesine were similar with the same productions of domestic and international Vindesine and could be used in the patients with lung cancer widely.

关 键 词：托马克 治疗 肺癌 Ⅲ期 

分 类 号：R734.205[医药卫生—肿瘤]